PanTher Therapeutics启动化疗贴片的第二次试验-动脉网

PanTher Therapeutics launches second trial for chemotherapy patch

Medical Device Network 等信源发布 2025-07-07 16:35



可切换为仅中文







The patch is being investigated in patients with pancreatic ductal adenocarcinoma. Image credit: Shutterstock / 3dMediSphere.

该贴片正在胰腺导管腺癌患者中进行研究。图片来源：Shutterstock / 3dMediSphere。

US-based PanTher Therapeutics has initiated a trial of its chemotherapy-eluting patch, which it hopes will make cancer therapy more tolerable.

总部位于美国的PanTher Therapeutics公司已经开始对其释放化疗药物的贴片进行试验，希望这种贴片能够使癌症治疗更易于耐受。

The Phase Ib study (NCT06673017) is investigating PTM-101 combined with neoadjuvant chemotherapy (FOLFIRINOX) in patients with

Ib期研究（NCT06673017）正在调查PTM-101联合新辅助化疗（FOLFIRINOX）在患者中的应用。

pancreatic ductal adenocarcinoma (PDAC).

胰腺导管腺癌 (PDAC)。

The study will investigate the safety, tolerability, and anti-tumour activity of two doses of PTM-101.

该研究将调查两种剂量的PTM-101的安全性、耐受性和抗肿瘤活性。

This non-randomised, open-label study plans to enrol approximately 30 treatment-naïve patients across multiple clinical sites in the US.

这项非随机、开放标签的研究计划在美国的多个临床站点招募大约30名未接受过治疗的患者。

Comprising a film-formulated version of paclitaxel, the drug-eluting patch is placed on the tumour site to provide continuous, high-dose, localised drug administration.

由紫杉醇制成的薄膜制剂组成，这种药物洗脱贴片放置在肿瘤部位，以提供持续、高剂量、局部的药物管理。

It follows a Phase I study (ACTRN12621000881831) that saw tumour shrinkage in patients treated with 100mg PTM-101 combined with standard of care (SoC) in borderline resectable and locally advanced PDAC.

此前的一项第一阶段研究 (ACTRN12621000881831) 显示，接受100毫克PTM-101联合标准治疗（SoC）的临界可切除和局部晚期PDAC患者出现了肿瘤缩小。

GlobalData Strategic Intelligence

全球数据战略情报

US Tariffs are shifting - will you react or anticipate?

美国关税正在变化——你会作出反应还是提前预料？

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

不要让政策变化让你措手不及。通过实时数据和专家分析保持主动性。

By GlobalData

由GlobalData提供

Learn more about Strategic Intelligence

了解有关战略情报的更多信息

PanTher Therapeutics CEO Laura Indolfi said: “The start of this second clinical trial of PTM-101 is an exciting milestone in our journey to transcend the dosing limitations of today’s cancer treatments by reimagining how chemotherapy is delivered.

PanTher Therapeutics首席执行官劳拉·因多尔菲表示：“PTM-101的第二项临床试验的开始是我们超越当今癌症治疗剂量限制的旅程中令人兴奋的里程碑，我们通过重新构想化疗的递送方式来实现这一目标。"

“Powerful cancer drugs exist, but their toxicity lowers maximum dose and limits dosing frequency, leaving too many opportunities for cancers to continue spreading while patients grapple with debilitating side effects.”

“强效的抗癌药物确实存在，但其毒性降低了最大剂量，限制了给药频率，使癌症在患者应对严重副作用的同时仍有太多机会继续扩散。”

Studies have shown that only 1% of systemically delivered chemotherapy reaches the tumour, with the remaining 99% of the drug producing toxic off-target effects, including neutropenia, hair loss, nausea and vomiting, and peripheral neuropathy.

研究表明，只有1%的全身化疗药物能够到达肿瘤，而剩余99%的药物则会产生脱靶毒性作用，包括中性粒细胞减少、脱发、恶心呕吐以及外周神经病变。

Therefore, PanTher hopes its more targeted treatment could provide higher benefits for patients whilst also carrying a more manageable safety profile with fewer off-target effects.

因此，PanTher希望其更具针对性的治疗可以为患者带来更高的益处，同时具有更易管理的安全性特征和更少的脱靶效应。

The company is also developing PTM-201 for the treatment of a range of other solid tumour types.

该公司还在开发PTM-201，用于治疗多种其他类型的实体瘤。

PanTher has not yet disclosed in which indication this therapy will be investigated, and it remains in the preclinical stages.

PanTher尚未披露将针对哪种适应症进行该疗法的研究，目前仍处于临床前阶段。

Other researchers are designing similar chemotherapy patches, including

其他研究人员也在设计类似的化疗贴片，包括

Starton Therapeutics,

斯塔顿治疗学，

which is developing combination patches that include six potential combinations of ingredients to enhance patient comfort and efficacy during chemotherapy treatment.

正在开发包含六种潜在成分组合的贴剂，以提高患者在化疗期间的舒适度和疗效。

注册获取我们的每日新闻汇总！

Give your business an edge with our leading industry insights.

利用我们领先的行业洞察，为您的企业带来优势。

Medical Device Network Excellence Awards - Have you nominated?

医疗器械网络卓越奖——您提名了吗？

Nominations are now open for the prestigious

提名现已开放，迎接这一享有盛誉的

Medical Device Network Excellence Awards

医疗器械网络卓越奖

- one of the industry's

- 行业中的